NCT00865410View on ClinicalTrials.gov

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions
Healthy
Interventions
DRUG

Abrika Bupropion 150 mg Extended-Released Tablet

A: Experimental Subjects received Abrika formulated products under fasting conditions

DRUG

Wellbutrin SR® 150 mg Extended-Release Tablet, single dose

B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions

Trial Locations (1)

33901

SFBC Ft. Myers, Inc., Fort Myers

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00865410 - A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter